Literature DB >> 19058308

Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients.

Walkíria Wingester Vilas-Boas1, Antônio Ribeiro-Oliveira, Renata da Cunha Ribeiro, Renata Lúcia Pereira Vieira, Jerusa Almeida, Ana Paula Nadu, Ana Cristina Simões e Silva, Robson Augusto Souza Santos.   

Abstract

AIM: To evaluate the effect of beta-blockade on angiotensins in the splanchnic and peripheral circulation of cirrhotic patients and also to compare hemodynamic parameters during liver transplantation according to propranolol pre-treatment or not.
METHODS: Patients were allocated into two groups: outpatients with advanced liver disease(LD) and during liver transplantation(LT). Both groups were subdivided according to treatment with propranolol or not. Plasma was collected through peripheral venipuncture to determine plasma renin activity(PRA), Angiotensin(Ang) I, Ang II, and Ang-(1-7) levels by radioimmunoassay in LD group. During liver transplantation, hemodynamic parameters were determined and blood samples were obtained from the portal vein to measure renin angiotensin system(RAS) components.
RESULTS: PRA, Ang I, Ang II and Ang-(1-7) were significantly lower in the portal vein and periphery in all subgroups treated with propranolol as compared to non-treated. The relationships between Ang-(1-7) and Ang I levels and between Ang II and Ang I were significantly increased in LD group receiving propranolol. The ratio between Ang-(1-7) and Ang II remained unchanged in splanchnic and peripheral circulation in patients under beta-blockade, whereas the relationship between Ang II and Ang I was significantly increased in splanchnic circulation of LT patients treated with propranolol. During liver transplantation, cardiac output and index as well systemic vascular resistance and index were reduced in propranolol-treated subgroup.
CONCLUSION: In LD group, propranolol treatment reduced RAS mediators, but did not change the ratio between Ang-(1-7) and Ang II in splanchnic and peripheral circulation. Furthermore, the modification of hemodynamic parameters in propranolol treated patients was not associated with changes in the angiotensin ratio.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058308      PMCID: PMC2773877          DOI: 10.3748/wjg.14.6824

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2005-02       Impact factor: 7.527

2.  Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

Authors:  Roberto J Groszmann; Guadalupe Garcia-Tsao; Jaime Bosch; Norman D Grace; Andrew K Burroughs; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; David Patch; Daniel S Matloff; Hong Gao; Robert Makuch
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

Review 3.  The therapeutic potential of Angiotensin-(1-7) as a novel Renin-Angiotensin System mediator.

Authors:  Ana Cristina Simões e Silva; Sérgio Veloso Brant Pinheiro; Regina Maria Pereira; Anderson José Ferreira; Robson Augusto Souza Santos
Journal:  Mini Rev Med Chem       Date:  2006-05       Impact factor: 3.862

Review 4.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

Review 5.  Liver cirrhosis and arterial hypertension.

Authors:  Jens H Henriksen; Soren Moller
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

6.  Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.

Authors:  R Bañares; E Moitinho; B Piqueras; M Casado; J C García-Pagán; A de Diego; J Bosch
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

Review 7.  Rethinking the renin-angiotensin system and its role in cardiovascular regulation.

Authors:  Pasquale Pagliaro; Claudia Penna
Journal:  Cardiovasc Drugs Ther       Date:  2005-01       Impact factor: 3.727

8.  The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7).

Authors:  Regina Maria Pereira; Robson Augusto Souza Dos Santos; Mauro Martins Teixeira; Virginia Hora Rios Leite; Lincoln Paiva Costa; Filipi Leles da Costa Dias; Lucíola S Barcelos; Guilherme Birchal Collares; Ana Cristina Simões e Silva
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

9.  Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2.

Authors:  G Paizis; C Tikellis; M E Cooper; J M Schembri; R A Lew; A I Smith; T Shaw; F J Warner; A Zuilli; L M Burrell; P W Angus
Journal:  Gut       Date:  2005-09-15       Impact factor: 23.059

10.  Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.

Authors:  Yao Hong Wei; Li Jun; Chen Ji Qiang
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

View more
  8 in total

Review 1.  Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.

Authors:  Ahmed A Magan; Atif A Khalil; Mohamed H Ahmed
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

2.  Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.

Authors:  Jianrong Wang; Wenxia Lu; Jingjing Li; Rong Zhang; Yuqing Zhou; Qin Yin; Yuanyuan Zheng; Fan Wang; Yujing Xia; Kan Chen; Sainan Li; Tong Liu; Jie Lu; Yingqun Zhou; Chuan-Yong Guo
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

3.  β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis.

Authors:  De-Run Kong; Jin-Guang Wang; Bin Sun; Ming-Quan Wang; Chen Chen; Fang-Fang Yu; Jian-Ming Xu
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

4.  Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome.

Authors:  Qi Fu; Tiffany B Vangundy; Shigeki Shibata; Richard J Auchus; Gordon H Williams; Benjamin D Levine
Journal:  Hypertension       Date:  2011-06-20       Impact factor: 10.190

5.  Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation.

Authors:  Syeda H Afroze; Md Kamruzzaman Munshi; Allyson K Martínez; Mohammad Uddin; Maté Gergely; Claudia Szynkarski; Micheleine Guerrier; Damir Nizamutdinov; David Dostal; Shannon Glaser
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-02-12       Impact factor: 4.052

6.  Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis.

Authors:  Walkíria Wingester Vilas-Boas; Antônio Ribeiro-Oliveira; Regina Maria Pereira; Renata da Cunha Ribeiro; Jerusa Almeida; Ana Paula Nadu; Ana Cristina Simões e Silva; Robson Augusto Souza dos Santos
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

7.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

Review 8.  Renin angiotensin system in liver diseases: Friend or foe?

Authors:  Ana Cristina Simões E Silva; Aline S Miranda; Natália P Rocha; Antônio L Teixeira
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.